DE60120366T2 - Aryl-kondensierte azopolycyclische Verbindungen - Google Patents

Aryl-kondensierte azopolycyclische Verbindungen Download PDF

Info

Publication number
DE60120366T2
DE60120366T2 DE60120366T DE60120366T DE60120366T2 DE 60120366 T2 DE60120366 T2 DE 60120366T2 DE 60120366 T DE60120366 T DE 60120366T DE 60120366 T DE60120366 T DE 60120366T DE 60120366 T2 DE60120366 T2 DE 60120366T2
Authority
DE
Germany
Prior art keywords
dodeca
tricyclo
aza
triene
pentadeca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60120366T
Other languages
German (de)
English (en)
Other versions
DE60120366D1 (de
Inventor
P.R.P. Pfizer Global Research Develo Groton BROOKS
J. W. Pfizer Global Research Develop Groton COE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60120366D1 publication Critical patent/DE60120366D1/de
Publication of DE60120366T2 publication Critical patent/DE60120366T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60120366T 2000-02-25 2001-02-08 Aryl-kondensierte azopolycyclische Verbindungen Expired - Lifetime DE60120366T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds
US514002 2000-02-25
PCT/IB2001/000153 WO2001062736A1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
DE60120366D1 DE60120366D1 (de) 2006-07-20
DE60120366T2 true DE60120366T2 (de) 2007-07-05

Family

ID=24045406

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60120366T Expired - Lifetime DE60120366T2 (de) 2000-02-25 2001-02-08 Aryl-kondensierte azopolycyclische Verbindungen
DE60140965T Expired - Lifetime DE60140965D1 (de) 2000-02-25 2001-02-08 Arylkondensierte azapolycyclische derivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60140965T Expired - Lifetime DE60140965D1 (de) 2000-02-25 2001-02-08 Arylkondensierte azapolycyclische derivate

Country Status (40)

Country Link
US (3) US6605610B1 (US07205300-20070417-C00032.png)
EP (2) EP1619192B1 (US07205300-20070417-C00032.png)
JP (1) JP2003524002A (US07205300-20070417-C00032.png)
KR (1) KR100537976B1 (US07205300-20070417-C00032.png)
CN (1) CN1263745C (US07205300-20070417-C00032.png)
AP (1) AP1860A (US07205300-20070417-C00032.png)
AT (2) ATE328872T1 (US07205300-20070417-C00032.png)
AU (2) AU784081B2 (US07205300-20070417-C00032.png)
BG (1) BG65891B1 (US07205300-20070417-C00032.png)
BR (1) BR0108610A (US07205300-20070417-C00032.png)
CA (1) CA2401229C (US07205300-20070417-C00032.png)
CR (1) CR6726A (US07205300-20070417-C00032.png)
CU (1) CU23148A3 (US07205300-20070417-C00032.png)
CY (1) CY1105301T1 (US07205300-20070417-C00032.png)
CZ (1) CZ303203B6 (US07205300-20070417-C00032.png)
DE (2) DE60120366T2 (US07205300-20070417-C00032.png)
DK (2) DK1619192T3 (US07205300-20070417-C00032.png)
DZ (1) DZ3328A1 (US07205300-20070417-C00032.png)
EA (1) EA005316B1 (US07205300-20070417-C00032.png)
EE (1) EE200200475A (US07205300-20070417-C00032.png)
ES (2) ES2336800T3 (US07205300-20070417-C00032.png)
GE (1) GEP20053454B (US07205300-20070417-C00032.png)
HK (1) HK1050894A1 (US07205300-20070417-C00032.png)
HR (1) HRP20020700A2 (US07205300-20070417-C00032.png)
HU (1) HU229482B1 (US07205300-20070417-C00032.png)
IL (2) IL150639A0 (US07205300-20070417-C00032.png)
IS (1) IS2293B (US07205300-20070417-C00032.png)
MA (1) MA26875A1 (US07205300-20070417-C00032.png)
MX (1) MXPA02008311A (US07205300-20070417-C00032.png)
NO (1) NO323608B1 (US07205300-20070417-C00032.png)
NZ (1) NZ519973A (US07205300-20070417-C00032.png)
OA (1) OA12181A (US07205300-20070417-C00032.png)
PL (1) PL365163A1 (US07205300-20070417-C00032.png)
PT (1) PT1259489E (US07205300-20070417-C00032.png)
RS (1) RS51123B (US07205300-20070417-C00032.png)
SI (1) SI1259489T1 (US07205300-20070417-C00032.png)
SK (1) SK12042002A3 (US07205300-20070417-C00032.png)
UA (1) UA74813C2 (US07205300-20070417-C00032.png)
WO (1) WO2001062736A1 (US07205300-20070417-C00032.png)
ZA (1) ZA200206768B (US07205300-20070417-C00032.png)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324013C (zh) * 1997-12-31 2007-07-04 辉瑞产品公司 芳基稠合氮杂多环化合物
KR100551183B1 (ko) * 2001-04-20 2006-02-13 화이자 프로덕츠 인크. 1,3-치환 인덴 및 아릴-융합 아자폴리시클릭 화합물의제조 방법
HUP0401967A2 (hu) * 2001-10-31 2005-01-28 Pfizer Products Inc. Nikotinsav-acetilkolin-receptor-agonisták alkalmazása nyugtalan láb szindróma kezelésére alkalmas gyógyszerkészítmények előállítására
DE60228478D1 (de) * 2001-11-30 2008-10-02 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
KR100892517B1 (ko) * 2001-11-30 2009-04-10 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물
RU2326693C2 (ru) 2002-07-18 2008-06-20 Цитос Байотекнолоджи Аг Конъюгаты гаптен-носитель и их применение
EP1554041B1 (en) * 2002-10-22 2012-05-23 EMD Millipore Corporation Multi-sided immersion formation of composite structures and method
AU2003278510B8 (en) * 2002-11-25 2008-07-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
CA2513293A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
JP2006528237A (ja) * 2003-05-20 2006-12-14 ファイザー・プロダクツ・インク バレニクリンの医薬組成物
SI1638971T1 (sl) * 2003-06-04 2008-12-31 Pfizer Prod Inc Priprava substituiranih kinoksalinov iz dianilinaz 2,3-dihidroksi-1,4-dioksanom
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
KR101096480B1 (ko) * 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
BRPI0607838A2 (pt) * 2005-02-24 2009-06-13 Pfizer Prod Inc preparação de uma quinoxalina substituìda de pureza elevada
KR20090007568A (ko) * 2006-04-24 2009-01-19 화이자 프로덕츠 인코포레이티드 약물 전달 장치용 비대칭 막
WO2008060487A2 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
JP5595926B2 (ja) * 2007-12-07 2014-09-24 アボット ゲーエムベーハー ウント カンパニー カーゲー ５−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
JP5645217B2 (ja) * 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
ES2398676T3 (es) * 2007-12-07 2013-03-20 Abbott Gmbh & Co. Kg Derivados de oxindol sustituidos con amidometilo y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (ja) * 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
CA2709774C (en) * 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
CN102388043A (zh) * 2009-02-11 2012-03-21 桑诺维恩药品公司 组胺h3反相激动剂和拮抗剂及其使用方法
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
WO2010151524A1 (en) * 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
TWI775817B (zh) 2017-03-03 2022-09-01 南韓商西梯茜生命工學股份有限公司 包含伐尼克蘭或其藥學上可接受鹽類的內含錯合物的口服藥物製劑
BR112022010021A2 (pt) * 2020-01-03 2022-08-16 Blue Oak Pharmaceuticals Inc Compostos e composições para tratamento de distúrbios do sistema nervoso central (snc)
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CN1324013C (zh) * 1997-12-31 2007-07-04 辉瑞产品公司 芳基稠合氮杂多环化合物
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
PL344010A1 (en) 1998-04-29 2001-09-24 Pfizer Prod Inc Aryl fused azapolycyclic compounds
CN1345320A (zh) * 1999-01-29 2002-04-17 艾博特公司 用作烟碱性乙酰胆碱受体配体的二氮杂二环衍生物
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1372692A4 (en) * 2001-03-19 2005-10-26 Sloan Kettering Inst Cancer ASYMMETRIC SYNTHESIS OF (S, S, R) - (-) - ACTINONE AND ITS ANALOG AND USES THEREOF
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
OA12181A (en) 2006-05-09
CZ20022778A3 (cs) 2003-09-17
ES2336800T3 (es) 2010-04-16
PT1259489E (pt) 2006-08-31
HRP20020700A2 (en) 2004-12-31
AU2005234671B2 (en) 2008-04-17
HUP0204580A2 (hu) 2003-04-28
US20030130260A1 (en) 2003-07-10
CR6726A (es) 2003-10-28
ATE328872T1 (de) 2006-06-15
BG65891B1 (bg) 2010-04-30
IS2293B (is) 2007-10-15
PL365163A1 (en) 2004-12-27
KR20030005209A (ko) 2003-01-17
US20030130261A1 (en) 2003-07-10
WO2001062736A1 (en) 2001-08-30
NO323608B1 (no) 2007-06-18
EP1619192A2 (en) 2006-01-25
YU59602A (sh) 2005-06-10
SI1259489T1 (sl) 2006-10-31
MA26875A1 (fr) 2004-12-20
SK12042002A3 (sk) 2004-02-03
KR100537976B1 (ko) 2005-12-21
EA005316B1 (ru) 2004-12-30
CU23148A3 (es) 2006-06-29
EP1619192B1 (en) 2009-12-30
AP1860A (en) 2008-07-02
BG106908A (bg) 2003-04-30
GEP20053454B (en) 2005-02-25
EE200200475A (et) 2003-12-15
HU229482B1 (en) 2014-01-28
AU2005234671A1 (en) 2005-12-15
EP1259489A1 (en) 2002-11-27
EP1619192A3 (en) 2006-03-22
UA74813C2 (en) 2006-02-15
AU2874801A (en) 2001-09-03
DZ3328A1 (US07205300-20070417-C00032.png) 2001-08-30
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
CN1263745C (zh) 2006-07-12
ZA200206768B (en) 2003-09-23
US7144882B2 (en) 2006-12-05
DE60120366D1 (de) 2006-07-20
NO20024042D0 (no) 2002-08-23
HUP0204580A3 (en) 2005-04-28
US6605610B1 (en) 2003-08-12
US7205300B2 (en) 2007-04-17
AP2002002604A0 (en) 2002-09-30
CA2401229C (en) 2007-10-02
CA2401229A1 (en) 2001-08-30
DK1619192T3 (da) 2010-03-29
HK1050894A1 (en) 2003-07-11
EA200200716A1 (ru) 2003-02-27
JP2003524002A (ja) 2003-08-12
ES2263640T3 (es) 2006-12-16
IL150639A0 (en) 2003-02-12
CY1105301T1 (el) 2010-03-03
DK1259489T3 (da) 2006-10-09
IS6459A (is) 2002-07-05
AU784081B2 (en) 2006-02-02
CZ303203B6 (cs) 2012-05-23
MXPA02008311A (es) 2002-12-09
BR0108610A (pt) 2002-11-19
EP1259489B1 (en) 2006-06-07
ATE453643T1 (de) 2010-01-15
DE60140965D1 (de) 2010-02-11
RS51123B (sr) 2010-10-31
CN1406227A (zh) 2003-03-26
IL150639A (en) 2011-10-31

Similar Documents

Publication Publication Date Title
DE60120366T2 (de) Aryl-kondensierte azopolycyclische Verbindungen
DE69839131T2 (de) Arylkondensierte azapolycyclische derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition